|Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2 …|
HA Burris III, HS Rugo, SJ Vukelja, CL Vogel, RA Borson, S Limentani, ...
Journal of Clinical Oncology 29 (4), 398-405, 2011
|Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer|
IE Krop, M Beeram, S Modi, SF Jones, SN Holden, W Yu, S Girish, ...
J Clin Oncol 28 (16), 2698-2704, 2010
|Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2–positive cancer|
PM LoRusso, D Weiss, E Guardino, S Girish, MX Sliwkowski
Clinical Cancer Research 17 (20), 6437-6447, 2011
|A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who were previously treated with …|
IE Krop, P LoRusso, KD Miller, S Modi, D Yardley, G Rodriguez, ...
Journal of clinical oncology 30 (26), 3234-3241, 2012
|Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion|
JS Powell, MV Ragni, GC White, JM Lusher, C Hillman-Wiseman, ...
Blood 102 (6), 2038-2045, 2003
|Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer|
S Girish, M Gupta, B Wang, D Lu, IE Krop, CL Vogel, HA Burris III, ...
Cancer chemotherapy and pharmacology 69 (5), 1229-1240, 2012
|Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability|
KA Poon, K Flagella, J Beyer, J Tibbitts, S Kaur, O Saad, JH Yi, S Girish, ...
Toxicology and applied pharmacology 273 (2), 298-313, 2013
|Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism|
BQ Shen, D Bumbaca, O Saad, Q Yue, C V Pastuskovas, ...
Current drug metabolism 13 (7), 901-910, 2012
|A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer|
M Beeram, IE Krop, HA Burris, SR Girish, W Yu, MW Lu, SN Holden, ...
Cancer 118 (23), 5733-5740, 2012
|Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)|
H Uppal, E Doudement, K Mahapatra, WC Darbonne, D Bumbaca, ...
Clinical Cancer Research 21 (1), 123-133, 2015
|Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors|
S Ramurthy, S Subramanian, M Aikawa, P Amiri, A Costales, J Dove, ...
Journal of medicinal chemistry 51 (22), 7049-7052, 2008
|Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2‐targeted antibody‐drug conjugate, in …|
M Gupta, PM LoRusso, B Wang, JH Yi, HA Burris III, M Beeram, S Modi, ...
The Journal of Clinical Pharmacology 52 (5), 691-703, 2012
|A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2 …|
BC Bender, F Schaedeli-Stark, R Koch, A Joshi, YW Chu, H Rugo, IE Krop, ...
Cancer chemotherapy and pharmacology 70 (4), 591-601, 2012
|Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor|
S Ramanathan-Girish, J McColm, JM Clements, P Taupin, S Barrowcliffe, ...
Antimicrobial agents and chemotherapy 48 (12), 4835-4842, 2004
|A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)|
M Beeram, HA Burris III, S Modi, M Birkner, S Girish, J Tibbitts, SN Holden, ...
Journal of Clinical Oncology 26 (15_suppl), 1028-1028, 2008
|Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma|
M Stroh, H Winter, M Marchand, L Claret, S Eppler, J Ruppel, O Abidoye, ...
Clinical Pharmacology & Therapeutics 102 (2), 305-312, 2017
|Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical …|
D Lu, S Girish, Y Gao, B Wang, JH Yi, E Guardino, M Samant, M Cobleigh, ...
Cancer chemotherapy and pharmacology 74 (2), 399-410, 2014
|Semi‐mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer|
VL Chudasama, F Schaedeli Stark, JM Harrold, J Tibbitts, SR Girish, ...
Clinical Pharmacology & Therapeutics 92 (4), 520-527, 2012
|AAPS workshop report: strategies to address therapeutic protein–drug interactions during clinical development|
S Girish, SW Martin, MC Peterson, LK Zhang, H Zhao, J Balthasar, ...
The AAPS journal 13 (3), 405-416, 2011
|Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer|
D Lu, H A Burris III, B Wang, E Claire Dees, J Cortes, A Joshi, M Gupta, ...
Current drug metabolism 13 (7), 911-922, 2012